Dr Lal Pathlabs Ltd Share Price – NSE  /  BSE

Healthcare, Small Cap

Banerjee is an alumnus of Delhi College of Engineering and SP Jain Institute of Management & Research, Mumbai. He has also done ‘BP Sales and Marketing Leadership Development Course’ at Kellogs, USA.

He joined Dr Lal PathLabs in July, 2014 as chief operating officer-Region II. Thereafter, he got promoted as chief growth officer and then moved to chief operating officer. Presently, he is serving as chief executive officer-associates/group companies.

He worked for Castrol India & BP Lubricants for 14 years and went on to become global market space manager. Later he joined Pidilite Industries as president – sales & marketing, Middle East & Africa.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).

The company reported a 53.98% surge in consolidated net profit of Rs 81.3 crore on 10.11% increase in revenue from operations to Rs 538.9 crore in Q3 FY24 over Q3 FY23.

The scrip declined 1.44% to end at Rs 2020.45 on Friday, 15 March 2024.

Powered by Capital Market - Live News

Uppilliappan’s last working day would be on or before 20 May 2024 (close of business hours). He will be taking up an external assignment post that.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).

The company reported a 53.98% surge in consolidated net profit of Rs 81.3 crore on 10.11% increase in revenue from operations to Rs 538.9 crore in Q3 FY24 over Q3 FY23.

The scrip fell 0.99% to currently trade at Rs 2,313.70 on the BSE.

Powered by Capital Market - Live News

Dr Lal Pathlabs has received affirmation in credit ratings from CARE for long term bank facilities of Rs 104.17 crore at CARE AA; Stable.

Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 1 February 2024, inter alia, have recommended the second interim dividend of Rs 12 per equity Share (i.e. 120%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News